Clinical Trials on HIV-1 Infections in France

Total 5860 results

ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Rennes University Hospital

Completed

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (BocepreVIH)

HIV-1 Infection | HCV Coinfection

France
Centre de Recherches et d'Etude sur la Pathologie...

Completed

Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. (RADAR)

HIV Infections | HIV-1 Infection

France
ANRS, Emerging Infectious Diseases

Completed

Gut-Associated Lymphocyte Trafficking (GALT)

HIV-1 Infection

France
ANRS, Emerging Infectious Diseases

Completed

Lipopeptide Immunisation With GTU-multiHIV Trial

HIV-1 Infection

France
Association de Recherche en Virologie et Dermatologie
ViiV Healthcare

Completed

Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy (MUTARESERVOIR)

HIV-1-infection

France
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Active, not recruiting

Reducing Antiretroviral Treatments (ALTAR)

HIV-1-infection

France
InnaVirVax

Completed

Phase I/IIa Dose-escalation Clinical Study of VAC-3S

HIV-1 Infection

France
Institut National de la Santé Et de la Recherche...

Recruiting

Quantification of Antisense HIV RNA in Patients

HIV-1-infection

France
Association de Recherche en Virologie et Dermatologie

Completed

Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES) (LAMRES)

HIV-1-infection

France
Centre de Recherches et d'Etude sur la Pathologie...
INSERM UMR S 1136

Completed

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients (ATALOW)

HIV-1 Infection

France
Objectif Recherche Vaccins SIDA

Completed

Exploration of HIV Reservoirs (MUCOVIR)

HIV-1 Infection

France
Assistance Publique - Hôpitaux de Paris
Gilead Sciences

Terminated

HCV, HBV, HIV Testing During Consultation With Anesthesiologist (SAHARA)

Hiv | HBV | HCV

France
University Hospital, Strasbourg, France

Unknown

Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation

HIV-1 Infection

France
Nantes University Hospital

Completed

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (SWAD)

HIV-1 Infection

France
Institut de Médecine et d'Epidémiologie Appliquée...
Sidaction

Unknown

Rosuvastatin to Decrease Residual Immune Activation in HIV Infection (CESAR)

HIV-1 Infection

France
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
ANRS, Emerging Infectious Diseases
Pfizer

Completed

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients (OPTIMAL)

HIV-1 Infection | AIDS

France
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France; ANRS, Emerging...

Completed

VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo (CellspermVIH) (CellspermVIH)

HIV-1-infection

France
ANRS, Emerging Infectious Diseases

Completed

4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients (ANRS162-4D)

HIV-1 Infection

France
University Hospital, Strasbourg, France

Unknown

Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients (DRONE)

HIV-1 Infection

France
Objectif Recherche Vaccins SIDA
Fondation Bettencourt-Schueller

Completed

Towards HIV Functional Cure (ULTRASTOP)

Chronic HIV-1 Infection

France
Objectif Recherche Vaccins SIDA
Merck Sharp & Dohme LLC; Pfizer; Cytheris SA

Completed

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)

HIV-1 Infection

United Kingdom, France, Italy, Spain
ANRS, Emerging Infectious Diseases
Gilead Sciences

Not yet recruiting

A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

HIV-1-infection

France
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (DATA)

HIV-1 Infection | Immunosuppression-related Infectious Disease

France
ANRS, Emerging Infectious Diseases

Recruiting

Primary Infection Cohort (PRIMO)

HIV-1-infection

France
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
Centre Hospitalier Universitaire de Nīmes
Institut de Génétique Moléculaire de Montpellier

Recruiting

Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment (RESERVIH32)

HIV-1-infection

France
Centre Hospitalier Universitaire Dijon

Completed

Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations (Mutapro)

HIV-1-infection

France
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection (OPTIPRIM-2)

HIV-1 Infection

France
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
Gilead Sciences

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

HIV-1 Infection

France, United Kingdom, Spain, Belgium, Ireland
Haitian Group for the Study of Kaposi's Sarcoma...
Harvard Medical School (HMS and HSDM); Brigham and Women's Hospital; Weill Medical... and other collaborators

Unknown

Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Antiretroviral Therapy | HIV-1-infection

Haiti
ANRS, Emerging Infectious Diseases

Completed

Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients (MICROGUT)

HIV-1 Infection

France
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Gilead Sciences

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

HIV-1 Infection

Spain, France, United States, Germany, Italy
University Hospital Center of Martinique
Clinique Antilles-Guyane; Fondation de France

Completed

Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana. (HP2V-AG)

1- Women | 2- HIV Infection | 3- Followed in West Indies and French Guiana for His Infection | 4- Acceptance of the Use of Nadis® Medical Files

Martinique
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

HIV-1 Infection

Kenya, Brazil, South Africa, Uganda, Zimbabwe, India, Malawi, Haiti, Thailand, Peru
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women

HIV-1 Infection

Peru, Malawi, South Africa, Zimbabwe, Haiti, Botswana, India
University Hospital, Rouen
Hoffmann-La Roche

Terminated

Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules (AMPHORE)

HIV Infections | HIV1 Infection

France
Bristol-Myers Squibb

Terminated

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

HIV-1 Infection

Thailand, United States, Australia, Canada, Spain, Colombia, South Africa, Hungary, France, Peru, Argentina, Chile, Mexico
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
Hendrik Streeck
Janssen, LP

Completed

Prospective Observational Cohort HIV & STI Study in Europe

HIV Infections | Sexual Behavior | HIV-1-infection | Risk Reduction

France, Hungary, Spain, Poland, Italy
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone (DOLUVOIR)

HIV-1 Infection

France
Janssen R&D Ireland

Completed

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

HIV-1 Infection

United States, Australia, France, United Kingdom, China, Belgium, Germany, Spain, Argentina, Romania, South Africa, Canada, Denmark, Netherlands, Chile, Puerto Rico, Austria, Russian Federation, Thailand, Sweden, Taiwan

3

Subscribe